Gudlevičienė Živilė, Žilinskas Kastytis, Kundrotas Gabrielis, Grubliauskaitė Monika, Baltriukienė Daiva, Bukelskienė Virginija
Department of Biobank, National Cancer Institute, Santariskiu Str. 1, 08660 Vilnius, Lithuania.
Department of Oncogynecology, National Cancer Institute, Santariskiu Str. 1, 08660 Vilnius, Lithuania.
Medicina (Kaunas). 2020 Oct 19;56(10):547. doi: 10.3390/medicina56100547.
Cancer incidence is growing with younger patients diagnosed with this disease every year. Improved cancer diagnostics and treatment lead to better survival of cancer patients. However, after aggressive chemo- or radiotherapy, cancer survivors suffer from various degrees of subfertility or infertility. Several fertility preservation technologies have been developed for young cancer patients: cryopreservation of germ cells, embryos, or reproductive tissues. The best results have been shown by cryopreservation of sperm and embryos. Yet the success of using cryopreserved oocytes or reproductive tissues (ovarian and testicular) is still insufficient. Therefore, this study was designed to assess the vitality, viability, general quality, and safety of frozen-thawed human ovarian tissue for retransplantation using modern molecular tests. The new miRNA array test was used to evaluate miRNA expression in thawed ovarian tissue in combination with standard xenotransplantation and pathological examination of microslides. Our results demonstrated that slow freezing is an efficient way (80%) to cryopreserve ovarian tissue with no structural damage afterwards. We have shown that xenotransplantation into immunodeficient mice, histology, and immunohistochemistry could be potentially replaced by more recent molecular methods. The latter method has shown that altered expression of miRNAs might be used as identifiers of normal/damaged tissue after further analysis. Newer, safer, and more specific approaches need to be developed in order to eliminate the risk of disease reoccurrence.
癌症发病率逐年上升，每年都有更年轻的患者被诊断出患有这种疾病。癌症诊断和治疗的改善使癌症患者的生存率提高。然而，在积极的化疗或放疗后，癌症幸存者会遭受不同程度的生育力下降或不育。针对年轻癌症患者已经开发了几种生育力保存技术：生殖细胞、胚胎或生殖组织的冷冻保存。精子和胚胎的冷冻保存显示出了最好的效果。然而，使用冷冻保存的卵母细胞或生殖组织（卵巢和睾丸）的成功率仍然不足。因此，本研究旨在使用现代分子检测方法评估冻融后人卵巢组织再移植的活力、生存能力、总体质量和安全性。新的miRNA阵列检测被用于结合标准异种移植和显微切片的病理检查来评估解冻后卵巢组织中的miRNA表达。我们的结果表明，慢速冷冻是一种有效的（80%）卵巢组织冷冻保存方法，之后不会造成结构损伤。我们已经表明，将其移植到免疫缺陷小鼠体内、组织学和免疫组织化学检测可能会被更新的分子方法所取代。后一种方法表明，miRNA表达的改变在进一步分析后可能用作正常/受损组织的标识符。需要开发更新、更安全、更特异的方法，以消除疾病复发的风险。
